Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330.

"CONFLICT OF INTEREST STATEMENT M.R.K. has licensed APX3330 through Indiana University Research and Technology Corporation to Apexian Pharmaceuticals LLC. R.M. is an employee of Apexian Pharmaceuticals. Apexian Pharmaceuticals had neither control nor oversight of the studies, interpretation, input, or presentation of the data in this manuscript. Apexian Pharmaceuticals has licensed APX3330 to Ocuphire Pharma for clinical trial studies in diabetic retinopathy and diabetic macular edema. M.R.K. is a co‐founder of Apexian Pharmaceuticals and is a medical consultant to Ocuphire Pharma who had neither control nor oversight of the studies, input, interpretation, or presentation of the data in this manuscript. All other authors declared no conflicts of interest related to this work."

"FUNDING INFORMATION M.R.K. was supported by grants from the National Institute of Health and National Cancer Institute R01CA167291, R01CA205166, R01CA231267, and R01CA254110 and NIH grants R01EY031939 and R01HL140961. M.R.K., R.E.S., and S.K.Q. are supported by the IU Simon Comprehensive Cancer Center, P30CA082709. M.R.K. and S.K.Q. are also supported by the Riley Children's Foundation. L.L.S., R.E.S., and S.K.Q. are also supported by The Indiana University School of Medicine Disease and Therapeutic Response Program which is funded in part by the Indiana Clinical and Translational Sciences Institute award UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders."